Paul Hallenbeck

Industry Perspective (Potential Leadership/Advisory Role)

Therapeutic Areas

Drug	Indication	Phase
SVV-001	Poorly Differentiated Neuroendocrine Carcinomas / High-Grade Neuroendocrine Tumors	Phase 1